Education and Training
- Fellow in Gastroenterology, Medicine, Memorial Sloan Kettering Cancer Center, 1976 - 1978
- Medical Resident, Medicine, Jewish Hospital (Canada), 1974 - 1976
- M.D.C.M., McGill University (Canada), 1973
Cardona, DM, Detweiler, CJ, Shealy, MJ, Sung, AD, Wild, DM, Poleski, MH, Balmadrid, BL, Cirrincione, CT, Howell, DN, and Sullivan, KM. "Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease." Archives of Pathology & Laboratory Medicine 142, no. 9 (September 2018): 1098-1105.
Sung, AD, Hassan, S, Cardona, DM, Wild, D, Nichols, KR, Mehdikhani, H, Balmadrid, B, Detweiler, CJ, Shealy, M, Cirrincione, C, Li, Z, Poleski, M, Dalton, TE, Siamakpour-Reihani, S, Chao, NJ, and Sullivan, KM. "Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 24, no. 4 (April 2018): 734-740.
Wild, D, Sung, AD, Cardona, D, Cirricione, C, Sullivan, K, Detweiler, C, Shealy, M, Balmadrid, B, Rowes, KL, Chao, N, Piryani, S, Karimabad, HM, Martin, P, and Poleski, M. "The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review." Digestive Diseases and Sciences 61, no. 3 (March 2016): 806-813.
Coutré, SE, Barrientos, JC, Brown, JR, de Vos, S, Furman, RR, Keating, MJ, Li, D, O'Brien, SM, Pagel, JM, Poleski, MH, Sharman, JP, Yao, N-S, and Zelenetz, AD. "Management of adverse events associated with idelalisib treatment: expert panel opinion." Leukemia & Lymphoma 56, no. 10 (January 2015): 2779-2786. (Review)
Shah, TU, Liddle, R, Branch, MS, Jowell, P, Obando, J, and Poleski, M. "Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial." Jop : Journal of the Pancreas 13, no. 5 (September 10, 2012): 514-518.
Faes, SK, Untch, BR, Edwards, C, Turner, J, Poleski, M, and Tyler, DS. "Management of Dieulafoy’s Lesions." (2010): 31-37.
Willett, CG, Duda, DG, Ancukiewicz, M, Shah, M, Czito, BG, Bentley, R, Poleski, M, Fujita, H, Lauwers, GY, Carroll, M, Tyler, D, Mantyh, C, Shellito, P, Chung, DC, Clark, JW, and Jain, RK. "A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer." Oncologist 15, no. 8 (2010): 845-851.
Duda, DG, Willett, CG, Ancukiewicz, M, di Tomaso, E, Shah, M, Czito, BG, Bentley, R, Poleski, M, Lauwers, GY, Carroll, M, Tyler, D, Mantyh, C, Shellito, P, Clark, JW, and Jain, RK. "Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer." Oncologist 15, no. 6 (2010): 577-583.
Xu, L, Duda, DG, di Tomaso, E, Ancukiewicz, M, Chung, DC, Lauwers, GY, Samuel, R, Shellito, P, Czito, BG, Lin, P-C, Poleski, M, Bentley, R, Clark, JW, Willett, CG, and Jain, RK. "Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer." Cancer Res 69, no. 20 (October 15, 2009): 7905-7910.
Willett, CG, Duda, DG, di Tomaso, E, Boucher, Y, Ancukiewicz, M, Sahani, DV, Lahdenranta, J, Chung, DC, Fischman, AJ, Lauwers, GY, Shellito, P, Czito, BG, Wong, TZ, Paulson, E, Poleski, M, Vujaskovic, Z, Bentley, R, Chen, HX, Clark, JW, and Jain, RK. "Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study." J Clin Oncol 27, no. 18 (June 20, 2009): 3020-3026.